The biotech scorecard for Q3: 15 stock

RyanPierse/GettyImagesHereisSTAT’sbiotechscorecard,ourregularledgerofstock-movingbiotechevents,forth CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy




leisure time

author：focus    Page View：1
Franklin faces
Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Prescription digital therapeutics are key to pharma’s future
Next article： Duchenne breakthrough therapy leaves behind pioneering families